Moleculin Reports 40% Remission Rate in AML Trial, Awaits Key Unblinding
Event summary
- Moleculin's MIRACLE trial shows 40% composite complete remission rate in 45 AML patients.
- First interim unblinding of data expected in June 2026 after 45-subject milestone.
- Company raised $8.3M in Q1 2026, extending runway into Q3 2026.
- Annamycin aims to reduce cardiotoxicity compared to standard anthracyclines.
The big picture
Moleculin's Annamycin represents a potential breakthrough in treating relapsed/refractory AML by addressing cardiotoxicity, a major limitation of existing anthracyclines. The upcoming unblinding of MIRACLE trial data will be critical in validating its efficacy, while the company's ability to secure further funding will determine its long-term viability in the competitive oncology space.
What we're watching
- Clinical Efficacy
- Whether the 40% remission rate holds upon unblinding in June 2026.
- Regulatory Pathway
- The pace at which Moleculin advances toward a Rolling NDA submission for AML.
- Financial Sustainability
- How Moleculin secures additional funding beyond Q3 2026 to support operations.
Related topics